Precision BioSciences (NASDAQ:DTIL) Raised to “Outperform” at BMO Capital Markets

BMO Capital Markets upgraded shares of Precision BioSciences (NASDAQ:DTIL) from a market perform rating to an outperform rating in a research report report published on Friday morning, MarketBeat.com reports. The firm currently has $34.00 price objective on the stock.

Precision BioSciences Stock Up 26.7 %

Shares of NASDAQ DTIL opened at $5.70 on Friday. The company has a current ratio of 9.22, a quick ratio of 9.22 and a debt-to-equity ratio of 0.34. The business has a 50-day moving average of $6.09 and a 200-day moving average of $8.27. The firm has a market capitalization of $43.72 million, a price-to-earnings ratio of 95.02 and a beta of 1.41. Precision BioSciences has a 12 month low of $3.61 and a 12 month high of $19.43.

Institutional Trading of Precision BioSciences

An institutional investor recently raised its position in Precision BioSciences stock. Geode Capital Management LLC boosted its position in Precision BioSciences, Inc. (NASDAQ:DTIL) by 40.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 65,974 shares of the company’s stock after acquiring an additional 19,088 shares during the quarter. Geode Capital Management LLC owned 0.86% of Precision BioSciences worth $591,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 37.99% of the company’s stock.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.